Concert Pharmaceuticals, Inc.

NasdaqGM:CNCE Voorraadrapport

Marktkapitalisatie: US$520.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Concert Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Roger Tung

Algemeen directeur

US$3.5m

Totale compensatie

Percentage CEO-salaris17.0%
Dienstverband CEO16.9yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn4.3yrs
Gemiddelde ambtstermijn bestuur16.3yrs

Recente managementupdates

Recent updates

Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

Jan 22
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

CinCor Pharma hits 52-week high on data for antihypertensive agent

Aug 08

Concert Pharmaceuticals: A Balanced Risk/Reward

Jun 15

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Jun 04
We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug

Jun 03

Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Jan 11
Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Aug 27
Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

May 25
We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Concert Pharma EPS beats by $0.02

May 04

Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Feb 27
Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia

Feb 01

Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Jan 23
Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

Dec 19
How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Nov 23
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Concert Pharma EPS beats by $0.15

Nov 05

Concert Pharma launches late-stage study of CTP-543 in hair loss disorder

Nov 03

Analyse CEO-vergoeding

Hoe is Roger Tung's beloning veranderd ten opzichte van Concert Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2022n/an/a

-US$127m

Jun 30 2022n/an/a

-US$125m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$4mUS$599k

-US$80m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$59m

Mar 31 2021n/an/a

-US$77m

Dec 31 2020US$3mUS$582k

-US$75m

Sep 30 2020n/an/a

-US$73m

Jun 30 2020n/an/a

-US$71m

Mar 31 2020n/an/a

-US$77m

Dec 31 2019US$3mUS$562k

-US$78m

Sep 30 2019n/an/a

-US$79m

Jun 30 2019n/an/a

-US$79m

Mar 31 2019n/an/a

-US$73m

Dec 31 2018US$5mUS$536k

-US$56m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

US$104m

Mar 31 2018n/an/a

US$104m

Dec 31 2017US$3mUS$517k

US$95m

Sep 30 2017n/an/a

US$89m

Jun 30 2017n/an/a

-US$50m

Mar 31 2017n/an/a

-US$50m

Dec 31 2016US$3mUS$500k

-US$51m

Compensatie versus markt: Roger's total compensation ($USD3.53M) is above average for companies of similar size in the US market ($USD2.48M).

Compensatie versus inkomsten: Roger's compensation has increased whilst the company is unprofitable.

CEO

Roger Tung (62 yo)

16.9yrs

Tenure

US$3,526,782

Compensatie

Dr. Roger D. Tung, Ph D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Richard Aldrich
Co-Founder & Independent Chairman of the Board16.8yrsUS$129.05k0.89%
$ 4.6m
Roger Tung
Co-Founder16.9yrsUS$3.53m1.37%
$ 7.1m
Marc Becker
Chief Financial Officer5.2yrsUS$1.38m0.20%
$ 1.0m
James Cassella
Chief Development Officer8.1yrsUS$1.51m0.13%
$ 674.6k
Nancy Stuart
Chief Operating Officer15.4yrsUS$1.58m0.27%
$ 1.4m
Justine Koenigsberg
Senior Vice President of Corporate Communications & Investor Relationsno datageen gegevensgeen gegevens
Jeffrey Munsie
Chief Legal Officer & Corporate Secretary3.5yrsgeen gegevens0.062%
$ 321.0k
Nabil Uddin
Vice President of Corporate Development1.2yrsgeen gegevensgeen gegevens
Kimberly Mack
Vice President of Human Resourcesless than a yeargeen gegevensgeen gegevens
Christine Boisclair
Senior Vice President of Regulatory Affairs & Quality Assurance1.2yrsgeen gegevensgeen gegevens

4.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: CNCE's management team is considered experienced (4.3 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Richard Aldrich
Co-Founder & Independent Chairman of the Board16.8yrsUS$129.05k0.89%
$ 4.6m
Roger Tung
Co-Founder16.9yrsUS$3.53m1.37%
$ 7.1m
Christine van Heek
Independent Director6.9yrsUS$99.05k0.041%
$ 214.7k
Peter Hutt
Independent Director16.3yrsUS$94.05k0.021%
$ 109.6k
Wilfred Jaeger
Independent Director16.8yrsUS$106.55k0%
$ 0
Jesper Hoiland
Independent Director3.9yrsUS$96.55k0.0082%
$ 42.9k
Thomas Auchincloss
Independent Director8.3yrsUS$109.05k0.028%
$ 147.5k

16.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: CNCE's board of directors are seasoned and experienced ( 16.3 years average tenure).